Health Economics›Thymoma›Advanced or metastatic disease subsequent lines of therapy

Advanced or metastatic disease subsequent lines of therapy

Thymoma · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Octreotide and Prednisone Variant #01	—	R 248 577	30d	—	—	~10	~R 2 485 768 indirect	—
Everolimus monotherapy Variant #01	—	R 18 360	28d	~6.0 mo	~18.1 mo	~2	~R 36 719 PFS proxy · indirect	15
Sunitinib monotherapy Variant #01	—	R 15 867	42d	~4.0 mo	—	~2	~R 31 733 PFS proxy · indirect	2
Octreotide monotherapy Variant #04	—	R 15 464	—	—	—	~2	~R 30 928 indirect	—
Ifosfamide monotherapy Variant #05	—	R 8 704	21d	~4.0 mo	~8.4 mo	~8	~R 69 635 PFS proxy · indirect	2
Capecitabine and Gemcitabine Variant #01	—	R 6 309	21d	—	~7.9 mo	~6	~R 37 856 PFS proxy · indirect	6

6 of 6 regimens shown